A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Assess The Safety, Tolerability, And Pharmacokinetics With 2-weeks Of Dosing Of Pf-06427878 In Overweight-obese, Otherwise Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Assess The Safety, Tolerability, And Pharmacokinetics With 2-weeks Of Dosing Of Pf-06427878 In Overweight-obese, Otherwise Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs PF 6427878 (Primary)
  • Indications Hyperlipidaemia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 03 May 2017 Status changed from recruiting to completed.
    • 08 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
    • 08 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top